Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form~* Histologically confirmed metastatic RCC~* Measurable disease, as defined by RECIST~* Age ≥ 18 years~* ECOG performance status of 0 or 1~* Prior nephrectomy~* Ability and capacity to comply with study and follow-up procedures~Exclusion Criteria:~* RCC with predominantly sarcomatoid features~* Prior systemic or adjuvant therapy for RCC~* Radiotherapy for RCC within 28 days prior to Day 1~* Prior treatment with bevacizumab, sunitinib, sorafenib, axitinib, thalidomide, or other similar agents~* Current need for dialysis~* Life expectancy of \< 12 weeks~* Current, recent, or planned participation in an experimental drug study~* Inadequate organ function~* Active infection or fever \> 38.5°C within 3 days of starting treatment~* History of other malignancies within 5 years prior to Day 1~* Any other medical conditions (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to provide informed consent, cooperate, or participate in the study, or to interfere with the interpretation of the results~* Inadequately controlled hypertension~* Prior history of hypertensive crisis or hypertensive encephalopathy~* New York Heart Association (NYHA) Class II or greater CHF~* History of myocardial infarction or unstable angina within 6 months prior to Day 1~* History of stroke or transient ischemic attack within 6 months prior to Day 1~* Known CNS disease except for treated brain metastasis~* Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1~* History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1~* Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)~* Major surgical procedure or anticipation of need for major surgical procedure during the course of the study~* Serious, non-healing wound; active ulcer; or untreated bone fracture~* Known hypersensitivity to any component of bevacizumab~* Pregnancy (positive pregnancy test) or lactation~* Current, ongoing treatment with full-dose warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).